Regulus Therapeutics Inc. (RGLS)

Market Cap	114.60M
Revenue (ttm)	n/a
Net Income (ttm)	-46.36M
Shares Out	66.24M
EPS (ttm)	-0.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,834,090
Open	1.500
Previous Close	1.500
Day's Range	1.480 - 1.750
52-Week Range	0.830 - 2.910
Beta	1.41
Analysts	Strong Buy
Price Target	11.80 (+582.08%)
Earnings Date	Mar 13, 2025

About RGLS

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. The company has a license and collaboration agreement with Alnylam Pharma...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 4, 2012
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: RGLS
• Website: https://www.regulusrx.com

Analyst Forecast

According to 5 analysts, the average rating for RGLS stock is "Strong Buy." The 12-month stock price forecast is $11.8, which is an increase of 582.08% from the latest price.

Price Target

$11.8

(582.08% upside)

Analyst Consensus: Strong Buy